Does Lokelma Raise Blood Pressure?
Lokelma (sodium zirconium cyclosilicate) does not directly raise blood pressure, but it can cause dose-dependent edema due to its sodium content, which may theoretically affect volume status in susceptible patients.
Mechanism and Sodium Content
Lokelma exchanges sodium for potassium in the gastrointestinal tract 1. Each 5 g dose contains 400 mg of sodium 1. This sodium exchange mechanism raises theoretical concerns about volume expansion and blood pressure effects, particularly in patients with hypertension, heart failure, or chronic kidney disease.
Clinical Evidence on Blood Pressure Effects
Direct Blood Pressure Data
The most robust evidence comes from the DIALIZE-Outcomes trial, which specifically evaluated volume status indicators in 2,690 patients on maintenance hemodialysis 2. This post hoc analysis found:
- No significant change in predialysis systolic blood pressure: -2.1 mm Hg with SZC versus -2.2 mm Hg with placebo
- No significant change in diastolic blood pressure: -0.9 mm Hg with SZC versus -0.8 mm Hg with placebo
- Similar antihypertensive medication use: 88% with SZC versus 86% with placebo during follow-up
- No increase in hypertension adverse events: 9% with SZC versus 8% with placebo 2
Edema as the Primary Concern
The most common adverse effect related to volume status is dose-dependent edema, not hypertension 3. In randomized trials, edema occurred but was not accompanied by clinically significant blood pressure increases. The 2021 Mayo Clinic hyperkalemia management guideline specifically notes that "the most common AEs were hypokalemia and a dose-dependent increase in edema" without listing hypertension as a significant adverse event 3.
Guideline Perspective
The 2025 AHA/ACC hypertension guidelines mention sodium zirconium cyclosilicate as a potassium-lowering binder to enable continuation of RAAS inhibitors in patients with hyperkalemia 4, 5. Importantly, these guidelines position SZC as a tool to maintain blood pressure control by allowing continuation of antihypertensive medications (ACE inhibitors, ARBs, mineralocorticoid receptor antagonists) that would otherwise need to be discontinued due to hyperkalemia.
Clinical Monitoring Recommendations
While Lokelma does not typically raise blood pressure, prudent monitoring includes:
- Watch for peripheral edema (the primary volume-related adverse effect)
- Monitor blood pressure in patients with heart failure or advanced CKD who may be more sensitive to sodium load
- Consider the 400 mg sodium per 5 g dose when calculating total daily sodium intake, particularly in sodium-sensitive patients
- Assess volume status clinically rather than assuming blood pressure will rise
Important Caveats
The absence of blood pressure elevation in clinical trials does not mean zero risk in all patients. Patients with:
- Severe heart failure with reduced ejection fraction
- Advanced CKD (especially those not yet on dialysis)
- Sodium-sensitive hypertension
- Baseline volume overload
...may theoretically be more susceptible to volume-related effects, though even in these populations, the DIALIZE-Outcomes trial showed no clinically meaningful blood pressure changes 2.
The benefit of maintaining RAAS inhibitor therapy (which Lokelma enables) typically outweighs concerns about sodium content, as RAAS inhibitors provide mortality and morbidity benefits that far exceed theoretical risks from the sodium in Lokelma 6, 7.